ERBB2 and breast cancer: In 2020 in Italy, out of the estimated 54,976 newly diagnosed BC, 38,841 (70.7%) are expected to be Luminal A-like, 4665 (8.5%) Luminal B-like, 4098 (7.5%) Triple-negative, 2281 (4.1%) HER2 enriched, and 5092 (9.3%) not specified.